Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic sp...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

Dahoom93 Sep. 5 at 1:32 PM

$JSPR

1 · Reply

Messerschmittbf109 Sep. 4 at 10:11 PM

$JSPR They don't have the slightest ability to understand that a stock is supported also and above all by the figure of the shareholders and by the ability to generate value in a practical sense. They have made mistakes and continue to do so as if it had never happened before. A capitalization killed by great geniuses in command. Embarrassing.

0 · Reply

BioTechChap Sep. 4 at 8:26 PM

$JSPR Was surprised that funding was not brought up. Next investor conference follows soon. If no questions on funding either, then I’m positive something is in the works and they’ve requested moderators not to mention funding topic in fireside chat for disclosure reasons.

1 · Reply

Messerschmittbf109 Sep. 4 at 6:48 PM

$THAR another pump and dump stock $VYNE $JSPR $IMMP hard times

0 · Reply

Messerschmittbf109 Sep. 4 at 2:24 PM

$SBET $KIDZ $JSPR Management? What management? I don’t see managers here ….

1 · Reply

Messerschmittbf109 Sep. 4 at 2:13 PM

$SBET $KIDZ $SOS $JSPR Dealing with people who think first of their own interests and then of everything else leads to this kind of performance. Incompetence? Lack of vision? Avoiding responsibility? Just being good at diluting and cutting. Ostrich behavior.

1 · Reply

Messerschmittbf109 Sep. 4 at 2:08 PM

$JSPR call ? Nothing to hear 👂… Zero

0 · Reply

Messerschmittbf109 Sep. 4 at 2:03 PM

$JSPR low board … low managers Embarrassing see it on nasdaq

0 · Reply

Dahoom93 Sep. 4 at 1:41 PM

$JSPR what happen ?

0 · Reply

DarkOrb Sep. 4 at 3:06 AM

$JSPR The replay is available. Definitely worth a listen as they provide more detail on the broken trial (they still don't know what happened, but it was not a simple bad batch, the drug was manufactured correctly). He did not discuss funding. They seemed to have decided 8 week dosing is optimal. 180mg (or 240mg) is probably the dose, 120mg being too low and 360mg being too high. More data around the end of the year. Still seemed optimistic. https://ir.jaspertherapeutics.com/events/event-details/cantor-fitzgerald-global-healthcare-conference-2025

0 · Reply

Jasper Therapeutics to Present at Upcoming Investor Conferences

Aug 13, 2025, 4:05 PM EDT - 24 days ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 11, 2025, 12:18 PM EDT - 2 months ago

JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jul 9, 2025, 8:00 AM EDT - 2 months ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jul 7, 2025, 1:25 PM EDT - 2 months ago

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Jul 7, 2025, 7:30 AM EDT - 2 months ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jun 14, 2025, 10:00 AM EDT - 3 months ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 3, 2025, 8:00 AM EDT - 3 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 12, 2025, 4:05 PM EDT - 4 months ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 1, 2025, 12:45 PM EST - 6 months ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 6 months ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 6 months ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 4:30 PM EST - 6 months ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 7 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 7 months ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 8 months ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 2, 2024, 4:30 PM EST - 9 months ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 10:09 AM EST - 10 months ago

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 13, 2024, 4:30 PM EST - 10 months ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 10 months ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 24, 2024, 8:00 AM EDT - 11 months ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 9:22 AM EDT - 11 months ago

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Oct 14, 2024, 7:00 AM EDT - 11 months ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Sep 4, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Jun 19, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

Jun 17, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit

Jun 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress

May 30, 2024, 6:05 PM EDT - 1 year ago

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

May 29, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments

May 13, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Briquilimab Development Program in Asthma

May 7, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at Upcoming Investor Conferences in May

Apr 2, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 21, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Mar 15, 2024, 8:00 AM EDT - 1 year ago

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Mar 4, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments

Feb 26, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference

Feb 23, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 7, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference

Feb 6, 2024, 8:59 AM EST - 1 year ago

Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock

Feb 5, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 2, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 5, 2024, 8:30 AM EST - 1 year ago

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

Jan 2, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics, Inc. Announces Reverse Stock Split

Dahoom93 Sep. 5 at 1:32 PM

$JSPR

1 · Reply

Messerschmittbf109 Sep. 4 at 10:11 PM

0 · Reply

BioTechChap Sep. 4 at 8:26 PM

1 · Reply

Messerschmittbf109 Sep. 4 at 6:48 PM

$THAR another pump and dump stock $VYNE $JSPR $IMMP hard times

0 · Reply

Messerschmittbf109 Sep. 4 at 2:24 PM

$SBET $KIDZ $JSPR Management? What management? I don’t see managers here ….

1 · Reply

Messerschmittbf109 Sep. 4 at 2:13 PM

1 · Reply

Messerschmittbf109 Sep. 4 at 2:08 PM

$JSPR call ? Nothing to hear 👂… Zero

0 · Reply

Messerschmittbf109 Sep. 4 at 2:03 PM

$JSPR low board … low managers Embarrassing see it on nasdaq

0 · Reply

Dahoom93 Sep. 4 at 1:41 PM

$JSPR what happen ?

0 · Reply

DarkOrb Sep. 4 at 3:06 AM

0 · Reply

Stmkr Sep. 3 at 5:44 PM

$JSPR Missed part of the callm anything on funding

0 · Reply

Messerschmittbf109 Sep. 3 at 1:42 PM

$CRVO pay attention for next spike up 😎weird books from days $RLMD $OTLK $VYNE $JSPR dynamic books

1 · Reply

NVDAMillionaire Sep. 3 at 7:14 AM

$JSPR Great piece that accurately captures JSPR's current position. So if you want to refresh your understanding of JSPR or learn about JSPR for the first time, this is essential reading. https://beyondspx.com/quote/JSPR/jasper-therapeutics-a-focused-bet-on-urticaria-amidst-financial-headwinds-nasdaq-jspr#analysis

0 · Reply

Bullshyte Sep. 2 at 9:13 PM

$JSPR hold tight...this will just go with a bang.

0 · Reply

cgchoi Sep. 2 at 10:04 AM

$JSPR ddd Wi

0 · Reply

elmono Aug. 29 at 8:22 AM

$JSPR not investable until they have brushed up their finances….out of cash around next read out, which may simply put a lid on any upside. They messed up and whole board should have been replaced 🤷‍♂️

0 · Reply

Messerschmittbf109 Aug. 28 at 5:55 PM

$JSPR I’ll sell in lose this disgusting stock Disappointment

0 · Reply

Messerschmittbf109 Aug. 27 at 9:33 PM

$CRVO $EVOK $IMMP $JSPR $VYNE of course -97 -99 my kids he would have done better . With his intuition.. So crazy people could pilot important companies and turnovers ,destroying them day after day

0 · Reply

Messerschmittbf109 Aug. 27 at 9:24 PM

$JSPR $CRVO $VYNE $IMMP $EVOK Except immutep + 24% in 5 years others have performance of 97-99% in 5 years Really embarrassing but board are in their stick seats …zero dignity

0 · Reply

Hereinbama35 Aug. 27 at 7:46 PM

$JSPR This was a $20 stock in January. Why am I buying this? Oh yeah, cuz I hate money.

2 · Reply

Drugtrade Aug. 26 at 3:49 PM

$JSPR lowered avg now have 1k shares, unlikely to add here

0 · Reply

FIREINSP Aug. 26 at 11:25 AM

$JSPR Lets have a lovely Green Day today folks…

0 · Reply

Market Cap	44.21M
Revenue (ttm)	0.00
Net Income (ttm)	-71.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	115,500
Avg Vol	727,038
Day's Range	N/A - N/A
Shares Out	16.25M
Stochastic %K	33%
Beta	2.77
Analysts	Strong Sell
Price Target	$14.29